Medivir’s investigator on the positive results directly from EASL
This week, Medivir presented positive final results from the phase Ib/IIa study on the combination of Fostrox and Lenvima for the treatment of advanced liver cancer. The results, presented at the EASL Liver Cancer Summit, demonstrate promising efficacy and safety. We spoke with Dr. Jeff Evans, one of the study investigators, directly from EASL in Paris.
Watch the interview with Dr. Jeff Evans below.
